Main Street Research LLC Sells 374,847 Shares of Boston Scientific Corporation $BSX

Key Points

• Main Street Research LLC sold 374,847 shares of Boston Scientific in Q3, slashing its stake by 98.3% to 6,446 shares valued at $629,000.
• CEO Michael F. Mahoney sold 160,901 shares at an average $93.49 (about $15.0M), trimming his ownership by 10.23%; insiders now hold roughly 0.50% of the stock while institutions own ~89.07%.
• Boston Scientific beat quarterly EPS estimates ($0.80 vs. $0.78) on $5.29B revenue (+15.9% YoY) and set Q1/FY2026 EPS guidance (0.780–0.800 / 3.430–3.490), but faces a class‑action suit over alleged misreported electrophysiology volumes amid recent analyst price‑target cuts and a consensus "Moderate Buy" $108 target.

Main Street Research LLC lessened its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 98.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,446 shares of the medical equipment provider's stock after selling 374,847 shares during the quarter. Main Street Research LLC's holdings in Boston Scientific were worth $629,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Steph & Co. bought a new stake in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific in the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp increased its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Finally, United Community Bank raised its stake in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares during the period. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX opened at $69.15 on Friday. The firm has a 50-day moving average of $82.47 and a 200-day moving average of $93.39. Boston Scientific Corporation has a one year low of $67.56 and a one year high of $109.50. The company has a market cap of $102.61 billion, a PE ratio of 35.64, a price-to-earnings-growth ratio of 0.96 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the business earned $0.70 EPS. Boston Scientific's revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Truist Financial reduced their price objective on Boston Scientific from $120.00 to $95.00 and set a "buy" rating for the company in a research report on Thursday, February 5th. Sanford C. Bernstein reissued an "outperform" rating and issued a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. BTIG Research restated a "buy" rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Wells Fargo & Company reduced their price target on Boston Scientific from $125.00 to $94.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. Finally, Morgan Stanley decreased their price target on shares of Boston Scientific from $130.00 to $118.00 and set an "overweight" rating for the company in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $108.00.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.50% of the stock is currently owned by company insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.